ClinicalTrials.gg
CompletedNCT05741528Updated Dec 11, 2025Results posted

An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic Medication

A Phase 3 interventional study of SEP-363856 in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 16 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-11.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
75
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing SEP-363856 in Schizophrenia — 1 open to participants now, 2 under way, 2 of them phase 3. SEP-363856 · Schizophrenia.

Enrollment
13th of 23
75 · median 83
Started
2023
with 1 other
Phase 3
9 of 23
1 open now
Registered
20th of 23
by date
Lead sponsor
18 of 23
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 23 studies testing SEP-363856 in Schizophrenia, this one is the 13th largest by enrollment, is one of 2 that started in 2023, is one of 9 in phase 3, and was the 20th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

1 of the 23 studies testing SEP-363856 in Schizophrenia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About SEP-363856

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing SEP-363856 in Schizophrenia, or all of them as a file.
02

Study summary

An Extension study to a clinical study that will continue to evaluate the effectiveness and safety of SEP-363856 in people with schizophrenia that switch to SEP-363856 from their current antipsychotic medication. This study will accept both male and female participants that have completed study SEP361-308. This study will be held in approximately 24 study sites in North America. Participation in the study will be approximately up to 25 weeks.

Read the detailed description

This is a 24-week, outpatient, multicenter, flexible-dose, open-label extension study designed to evaluate the long-term safety and tolerability of SEP-363856 (50 to 100 mg/day) for the treatment of subjects with schizophrenia who have completed Study SEP361-308 treatment period, during which they were switched from a previous antipsychotic treatment to SEP-363856.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: (list is not all inclusive)

  • Subject has given written and privacy authorization prior to participation in the study.
  • Subject has completed the Treatment Period of Study SEP361-308.
  • Subject has not taken any psychotropic medication other than the study drug, pre-switch antipsychotic and protocol-allowed medications during Study SEP361-308.
  • Female subject must have a negative rapid urine pregnancy test at the End of Treatment (EOT) Visit of Study SEP361-308.

Exclusion Criteria: (list is not all inclusive)

  • Subject is suicidal based on the Columbia - Suicide Severity Rating Scale (C-SSRS) assessment at the End of Treatment (EOT) Visit of Study SEP361-308.
  • Subject has a abnormality including physical examination, vital signs, or finding at the End of Treatment (EOT) Visit of Study SEP361-308.
  • Subject has a positive rapid urine drug screen at the EOT Visit of Study SEP361-308.
  • Female subject is pregnant or lactating.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
75 participants (actual)

Study arms

  • Experimental
    SEP-363856

    Drug: SEP-363856

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs)

    An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease occurring after the administration of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product.

    Time frame: From first dose of study drug up to end of 1 week follow up period (up to Week 25)

  2. Number of Participants With Serious Adverse Events

    An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease occurring after the administration of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. A serious adverse event is any AE occurring at any dose that results in death, is life-threatening, results in persistent or significant disability/incapacity, requires in-patient hospitalization or prolongation of existing hospitalization, or is a congenital anomaly/birth defect.

    Time frame: From first dose of study drug up to end of 1 week follow up period (up to Week 25)

  3. Number of Participants With AEs Leading to Discontinuation of Study

    An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease occurring after the administration of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. AEs leading to discontinuation from the study are those AEs which caused participant to discontinue from the study.

    Time frame: From first dose of study drug up to end of 1 week follow up period (up to Week 25)

07

Results

Posted Nov 12, 2025

Participant flow

Participants took part in the study at 16 clinical sites in the United States (US) from 31 March 2023 to 23 September 2024.

Participant flow — Overall Study
MilestoneSEP-363856
Started75
Completed56
Not completed19
Withdrew: Withdrawal by subject11
Withdrew: Lost to follow-up3
Withdrew: Adverse event2
Withdrew: Non-compliance with study drug2
Withdrew: Reason not specified1

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs)

An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease occurring after the administration of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product.

Time frame:
From first dose of study drug up to end of 1 week follow up period (up to Week 25)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsSEP-363856
Number of Participants With Adverse Events (AEs)28
PrimaryNumber of Participants With Serious Adverse Events

An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease occurring after the administration of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. A serious adverse event is any AE occurring at any dose that results in death, is life-threatening, results in persistent or significant disability/incapacity, requires in-patient hospitalization or prolongation of existing hospitalization, or is a congenital anomaly/birth defect.

Time frame:
From first dose of study drug up to end of 1 week follow up period (up to Week 25)
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events
ParticipantsSEP-363856
Number of Participants With Serious Adverse Events4
PrimaryNumber of Participants With AEs Leading to Discontinuation of Study

An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease occurring after the administration of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. AEs leading to discontinuation from the study are those AEs which caused participant to discontinue from the study.

Time frame:
From first dose of study drug up to end of 1 week follow up period (up to Week 25)
Reported as:
Count of participants · Participants
Number of Participants With AEs Leading to Discontinuation of Study
ParticipantsSEP-363856
Number of Participants With AEs Leading to Discontinuation of Study1

Adverse events

Collected over From first dose of study drug up to end of 1 week follow up period (up to Week 25). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SEP-3638560/75 (0%)4/75 (5.3%)9/75 (12%)
Most frequent serious events
Most frequent serious events
EventSEP-363856
DelusionPsychiatric disorders1/75
Psychotic disorderPsychiatric disorders1/75
SchizophreniaPsychiatric disorders1/75
HypotensionVascular disorders1/75
Most frequent other events
Most frequent other events
EventSEP-363856
Weight decreasedInvestigations5/75
C-reactive protein increasedInvestigations4/75

Baseline characteristics

Safety population included all participants who received at least one dose of study drug during the 24-week open-label extension (OLE) treatment period.

Age, Continuous
Age, Continuous(years)SEP-363856
Mean49.7 ± 11.41
Sex: Female, Male
Sex: Female, Male(Participants)SEP-363856
Female22
Male53
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)SEP-363856
Race — Asian2
Race — Black or African American49
Race — White23
Race — Multiracial1
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)SEP-363856
Ethnicity — Hispanic or Latino13
Ethnicity — Not Hispanic or Latino62
08

Study locations

16 sites
  • Research Site
    Anaheim, California 92805, United States
  • Research Site
    Bellflower, California 90706, United States
  • Research Site
    Garden Grove, California 92845, United States
  • Research Site
    Lemon Grove, California 91945, United States
  • Research Site
    Santee, California 92071, United States
  • Research Site
    Torrance, California 90502, United States
  • Research Site
    Hollywood, Florida 33021, United States
  • Research Site
    Miami, Florida 33122, United States
  • Research Site
    Atlanta, Georgia 30318, United States
  • Research Site
    Atlanta, Georgia 30331, United States
  • Research Site
    Chicago, Illinois 60640, United States
  • Research Site
    Gaithersburg, Maryland 20877, United States
  • Research Site
    Berlin, New Jersey 08009, United States
  • Research Site
    Charlotte, North Carolina 28211, United States
  • Research Site
    Hickory, North Carolina 28601, United States
  • Research Site
    Richardson, Texas 75080, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing. Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/

Data sharing details ↗ · clinical-trials.otsuka.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Sep 2024, 17 months.

Results were first posted in Nov 2025, 1 year 1 month after primary completion.

Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 17 months is below that.

Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2023
First posted
Feb 23, 2023
StartActual
Mar 31, 2023
Primary completionActual
Sep 23, 2024
CompletionActual
Sep 23, 2024
Results first posted
Nov 12, 2025
Last update
Dec 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05741528
Responsible party
Sponsor
First posted
Feb 23, 2023
Start date
Mar 31, 2023
Primary completion
Sep 23, 2024
Completion
Sep 23, 2024
Results posted
Nov 12, 2025
Last update
Dec 11, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SEP-363856

Start the discussion